Insider Transactions in Q4 2020 at Staar Surgical CO (STAA)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2020
|
John C Moore Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
11,387
-100.0%
|
$819,864
$72.46 P/Share
|
|
Nov 23
2020
|
James E Francese Sr. VP, Comm. Ops., NA, APAC |
SELL
Open market or private sale
|
Direct |
18,959
-26.95%
|
$1,516,720
$80.13 P/Share
|
|
Nov 23
2020
|
James E Francese Sr. VP, Comm. Ops., NA, APAC |
BUY
Exercise of conversion of derivative security
|
Direct |
18,959
+11.93%
|
$208,549
$11.45 P/Share
|
|
Nov 23
2020
|
Hans Martin Blickensdoerfer Sr. VP, Comm. Ops, China |
SELL
Open market or private sale
|
Direct |
4,774
-2.13%
|
$396,242
$83.08 P/Share
|
|
Nov 23
2020
|
Hans Martin Blickensdoerfer Sr. VP, Comm. Ops, China |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+1.65%
|
$28,500
$15.54 P/Share
|
|
Nov 20
2020
|
Hans Martin Blickensdoerfer Sr. VP, Comm. Ops, China |
SELL
Open market or private sale
|
Direct |
2,688
-2.36%
|
$223,104
$83.02 P/Share
|
|
Nov 19
2020
|
Hans Martin Blickensdoerfer Sr. VP, Comm. Ops, China |
SELL
Open market or private sale
|
Direct |
14,007
-10.95%
|
$1,148,574
$82.03 P/Share
|
|
Nov 19
2020
|
Hans Martin Blickensdoerfer Sr. VP, Comm. Ops, China |
SELL
Exercise of conversion of derivative security
|
Direct |
12,156
-8.68%
|
$996,792
$82.02 P/Share
|
|
Nov 19
2020
|
Hans Martin Blickensdoerfer Sr. VP, Comm. Ops, China |
BUY
Exercise of conversion of derivative security
|
Direct |
12,156
+7.98%
|
$182,340
$15.54 P/Share
|
|
Nov 16
2020
|
Scott D Barnes Chief Medical Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
22,593
-52.56%
|
$1,807,440
$80.25 P/Share
|
|
Nov 16
2020
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,593
+22.96%
|
$722,976
$32.89 P/Share
|
|
Nov 09
2020
|
Keith Holliday Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
23,714
-40.85%
|
$1,920,834
$81.56 P/Share
|
|
Nov 09
2020
|
Keith Holliday Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,714
+28.03%
|
$309,712
$8.41 P/Share
|
|
Nov 09
2020
|
Jon K. Hayashida VP, Global Clinical, Medical |
SELL
Open market or private sale
|
Direct |
20,000
-64.95%
|
$1,620,000
$81.34 P/Share
|
|
Nov 09
2020
|
Jon K. Hayashida VP, Global Clinical, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+28.42%
|
$440,000
$22.97 P/Share
|
|
Nov 09
2020
|
John C Moore Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
14,254
-55.59%
|
$1,140,320
$80.88 P/Share
|
|
Nov 09
2020
|
John C Moore Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,206
-88.45%
|
$1,312,686
$81.03 P/Share
|
|
Nov 09
2020
|
John C Moore Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,206
+28.11%
|
$226,884
$14.06 P/Share
|